The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Presentation
PHASE 1B/2 FIRST-IN-CLASS NOVEL COMBINATION TRIAL OF NEXT GENERATION CDK4-SELECTIVE INHIBITOR PF-07220060 AND NEXT GENERATION CDK2-SELECTIVE INHIBITOR PF-07104091 IN HR+ HER2- METASTATIC BREAST CANCER AND ADVANCED SOLID TUMORS
Yap T, Yan F, Sadeghi S, Lin T, Liu F, Malky L, Golmakani M, Moreau A, Neumann H, Zhou L, Juric D, Sharma M
Tegtociclib (PF-07104091) + Atirmociclib (PF-07220060) | September 13, 2024 | ESMO 2024
C4391002 | NCT05262400
